Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

Background: Cisplatin is used to treat head and neck cancer. People who take this drug are at risk for hearing loss. Atorvastatin is a drug used to treat high cholesterol. It might reduce the risk of cisplatin-induced hearing loss. Objective: To find out if atorvastatin reduces hearing loss in people treated with cisplatin and radiation. Eligibility: People ages 18 and older with squamous cell carcinoma of the head and neck who will undergo treatment with cisplatin-based chemotherapy and radiation Design: Participants will be screened with their medical records. Participants currently

Trial Details

NCT ID

NCT04915183

Phase

PHASE2

Sponsor

National Institute on Deafness and Other Communication Disorders (NIDCD)

Status

RECRUITING

Cancer Type

Head and Neck Cancer

Interventions

Placebo
Atorvastatin

Locations (sample)

Atlanta, Georgia, United States|33.749,-84.38798
Baltimore, Maryland, United States|39.29038,-76.61219
Bethesda, Maryland, United States|38.98067,-77.10026
Rochester, New York, United States|43.15478,-77.61556
Fairfax, Virginia, United States|38.84622,-77.30637

Key Eligibility Criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria evaluated by the study team, including …
Willingness and ability to comply with and participate in all study procedures and availability for the duration of the study
Ability to provide consent and provision of signed and dated informed consent form
Adult subjects, aged \>=18

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →